The DSM 5 revolution of anxiety disorderconceptual background and practical implications

Prof. Joseph Zohar

Tel-Aviv University Israel

Classification

Over the past 30 years the diagnosis has been focused on clinically based
 Syndromes.

 Disorders were defined as Syndromes, i.e symptoms that have been observed to co-vary together in individuals

DSM-IV – Descriptive approach

DSM IV Classification of Anxiety Disorders





The phenotype might be misleading

Syndromes appearing
 clinically similar

may result from

distinct etiology.

e.g. diabetes mellitus.

diabetes mellitus >

destruction of islet cells

versus

insulin resistance

A different approach is to look beyond the symptoms

To try to provide a better match between research in neuroscience and

classification



Descriptive

♦ Biomarkers

Syndromes

Dimensional





Endophenotypical Approach



Endophenotypical Approach

Diagnosis in Psychiatry: Can an Enclophenotypical Approach Help?

Bio-signatures

Anxiety

 Integration of Validators derived from neuro-science advances.

- Genetics
- Neuroimaging
- Cognitive Science
- Pathophysiology





Brain Circuitry

OCD has: a.Specific brain circuitry:

Prefrontal cortex - temporal cortex - thalamus - basal ganglia Is OCD part of Anxiety disorder ?

 Cortical- Basal circuit abnormalities in OCD

VS.

Limbic circuit abnormalities in GAD ,SAnD and PD.



Integration of validators derived from scientific advances in the last few decades:

Genetics

Neuroimaging

Cognitive Science

Pathophysiology



Cognitive Science

- NIMH is launching the Research Domain
 Criteria (RDoC) project.
- Fear extinction (instead of anxiety)
- Emotional bias (negative emotionality) (depression)
- Cognitive deficits (schizophrenia)
- Cognitive inflexibility (eg reversal learning) (OCD)
- Impulsivity
- Temperament

Possible tools to explore endophenotype

- Family aggregation
- Pharmacological dissection
- Pharmacological challenge
- Cognitive challenge
- Brain structure
- Brain Circuitry
- Epigenetic tools

In OCD patients and their

clinically

unaffected close relatives.

Orbitofrontal Dysfunction in Patients with Obsessive-Compulsive Disorder and Their Unaffected Relatives

Samuel R. Chamberlain,^{1,2,3}* Lara Menzies,^{1,2,3} Adam Hampshire,⁴ John Suckling,^{1,2} Naomi A. Fineberg,^{1,3} Natalia del Campo,^{1,2} Mike Aitken,^{2,5} Kevin Craig,^{1,2,3} Adrian M. Owen,⁴ Edward T. Bullmore,^{1,2,6} Trevor W. Robbins,^{2,5} Barbara J. Sahakian^{1,2}

SCIENCE VOL 321 18 JULY 2008

Researchers identified abnormally reduced activation of several cortical regions, including the orbitofrontal cortex, during reversal learning in OCD patients and their clinically unaffected close relatives, supporting the existence of an underlying endophenotype for this disorder.

Endophenotypical Approach

Basis of classification

changes in "anxiety"

in DSM 5

Diagnoses of **anxiety** disorders

DSM IV Classification of Anxiety Disorders



DSM IV

Anxiety

Disorders

DSM 5

Anxiety Disorders

Stress Related Disorders

OCD and OCD Spectrums

1 Family

3 Families
Section II: Diagnostic Criteria and Codes

- * Neurodevelopmental Disorders
- * Schizophrenia Spectrum and Other Psychotic Disorders
- * Bipolar and Related Disorders
- * Depressive Disorders
- * Anxiety Disorders
- * Obsessive-Compulsive and Related Disorders
- * Trauma- and Stressor-Related Disorders
- * Dissociative Disorders
- * Somatic Symptom and Related Disorders
- * Feeding and Eating Disorders
- * Elimination Disorders
- * Sleep-Wake Disorders
- * Sexual Dysfunctions
- * Gender Dysphoria
- * Disruptive, Impulse-Control, and Conduct Disorders
- * Substance-Related and Addictive Disorders

Section II: Diagnostic Criteria and Codes

- * Neurodevelopmental Disorders
- * Schizophrenia Spectrum and Other Psychotic Disorders
- * Bipolar and Related Disorders
- * Depressive Disorders
- * Anxiety Disorders
- * Obsessive-Compulsive and Related Disorders
- * Trauma- and Stressor-Related Disorders
- * Dissociative Disorders
- * Somatic Symptom and Related Disorders
- * Feeding and Eating Disorders
- * Elimination Disorders
- * Sleep-Wake Disorders
- * Sexual Dysfunctions
- * Gender Dysphoria
- * Disruptive, Impulse-Control, and Conduct Disorders
- * Substance-Related and Addictive Disorders

DSM IV

Anxiety

Disorders

DSM 5

Anxiety Disorders

Stress Related Disorders

OCD and OCD Spectrums

1 Family

3 Families



OCD and OCD Spectrums

Obsessive-Compulsive Disorder Body Dysmorphic Disorder Hoarding Disorder Trichotillomania (Hair-Pulling Disorder) Excoriation (Skin-Picking) Disorder Substance/Medication-Induced Obsessive-Compulsive and Related Disorder **Obsessive-Compulsive and Related Disorder Due to Another Medical Condition Other Specified Obsessive-Compulsive and Related** Disorder **Unspecified Obsessive-Compulsive and Related Disorder**



Stress Related Disorders

Reactive Attachment Disorder Disinhibited Social Engagement Disorder Post Traumatic Stress Disorder Acute Stress Disorder Adjustment Disorders Other Specified Trauma- and Stressor-Related Disorder Unspecified Trauma- and Stressor-Related Disorder

What is unique about stress related disorders ?

What is unique about PTSD?

Clear point of onset.



VOLUME 18 | NUMBER 4 | APRIL 2012 NATURE MEDICINE



Window of opportunity

"Golden hours"

Treatment of Chronic PTSD



"Window of Opportunities"



What do we do with patients who come to the ER after experiencing a trauma? What do we do with patients who come to the ER after experiencing a trauma?

- Talk with them about the trauma
- Encourage them not to suppress, not to repress



PTSD Diagnosis

Trauma **Re-experiencing** Avoidance Numbing Increased arousal

Time requirement – at least **over a month** after the exposure

Clinically significant distress or impairment of functioning

PTSD: Re-experiencing Symptoms

- ☑ Recurrent, intrusive, distressing recollections
- ☑ Recurrent, distressing dreams
- ☑ Flashbacks/Re-living
- ☑ Triggers lead to intense psychological distress
- ☑ Triggers lead to intense physiological reactivity

Re-experiencing Haunted by the memory of the event

The past is always present





Re-experiencing the traumatic memory of the event

What would happen if we erase the traumatic memory?





Consolidation

The transition from unstable memory to stable memory.

PTSD



Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval

Karim Nader, Glenn E. Schafe & Joseph E. Le Doux

NATURE VOL 406 17 AUGUST 2000 www.nature.com

What will be the effect of administration of **anisomycin** (protein-synthesis inhibitor) on PTSD ?

Translational Research





Treatment : Anisomycin – a Protein Synthesis Inhibitor



Cohen H, Kaplan Z, Matar M, Loewenthal U, Kozlovsky N, Zohar J. 2006 Anisomycin, a Protein Synthesis Inhibitor, Disrupts Traumatic Memory Consolidation and Attenuates Post Traumatic Stress Response in Rats.

Back to the clinic...

If a reduction in fear memories associated with trauma is beneficial, then:

Would amnesia of traumatic events reduce the rate of PTSD ?

Does **amnesia** of traumatic events **decrease** the risk for PTSD?





Does Memory of a Traumatic Event Increase the Risk for Posttraumatic Stress Disorder in Patients With Traumatic Brain Injury? A Prospective Study

Sharon Gil, Ph.D.

Yael Caspi, Ph.D.

Irit Zilberman Ben-Ari, Ph.D.

Danny Koren, Ph.D.

Ehud Klein, M.D.

(Am J Psychiatry 2005; 162:963-969)

(Am J Psychiatry 2005; 162:963-969)

6% of individuals with no memory of the traumatic event 24 hours after the event, presented PTSD symptoms at 6 months, as opposed to 23% in individuals with memory of the traumatic event

The Relation Between Memory of the Traumatic Event and PTSD: Evidence From Studies of Traumatic Brain Injury

Ehud Klein, MD¹, Yael Caspi, ScD, MA², Sharon Gil, PhD³

Can J Psychiatry, Vol 48, No 1, February 2003

Impaired memory for the traumatic events seems to reduce the risk for developing PTSD.

Pharmacologic disruption of traumatic memories might be therapeutically beneficial in people with PTSD If a reduction in fear memories associated with trauma is beneficial, then:

Amnesia of traumatic events reduces the rate of PTSD
How can we

amnesia?



What type of "defense mechanism" mimics amnesia?

If a reduction in fear memories associated with trauma is beneficial, then:

a) Amnesiab) A repressive coping style

Repressive Coping Style

Repressive coping style – cognitive and emotional effort to ignore or divert attention from a threat

Roth & Cohen (1986), Am Psychol, 41: 813-9

If a reduction in fear memories associated with trauma is beneficial, then:

Would repressive coping style be beneficial ?

Repressive Coping Style, Acute Stress Disorder, and PTSD After Myocardial Infarction

Ginzburg et al, Psychosomatic Medicine (2002) 64(5) 748-757

Repressive Coping Style

	Repressive	Low	High Anxious	Defensive
	N=28	Anxious	N=36	N=29
		N=20		
Sub- clinical ASD	14.3%	10%	27.8%	20.7%
Clinical ASD	3.6%	0%	36.1%	20.7%
Sub- clinical PTSD	10.7%	10%	44.4%	37.9%
Clinical PTSD	7.1%	20%	19.4%	17.2%

Ginzburg et al (2002), Psychosomatic Medicine 64: 748-757

Repressive Coping Style

Avoidance, suppression and denial (avoidance coping strategies) are effective in reducing traumatic stress-induced distress

> Lazarus, RS (1983) The Costs and Benefits of Denial. In S Breztitz (ed), The denial of stress

If a reduction in fear memories associated with trauma is beneficial, then:

Psychological interventions which **enhance** memories of the trauma (e.g. **debriefing**) – How does it fit in?

Would they be associated with a better / worse out-come ?



Debriefing is a "must" in early intervention

Psychological debriefing for road traffic accident victims Mayou et al

British Journal of Psychiatry, 2000, 176:589-593



Mayou et al 2000





Emotional or educational debriefing after psychological trauma*

Randomised controlled trial

MARIT SIJBRANDIJ, MIRANDA OLFF, JOHANNES B. REITSMA, INGRID V. E. CARLIER and BERTHOLD P. R. GERSONS

BRITISH JOURNAL OF PSYCHIATRY (2006), 189, 150-155. doi: 10.1192/bjp.bp.105.021121

Method We randomised 236 adult survivors of a recent traumatic event to either emotional ventilation debriefing, educational debriefing or no debriefing (control) and followed up at 2 weeks, 6 weeks and 6 months.

Results Psychiatric symptoms decreased in all three groups over time, without significant differences between the groups in symptoms of PTSD (P=0.33). Participants in the emotional debriefing group with high baseline hyperarousal score had significantly more PTSD symptoms at 6 weeks than control participants (P=0.005).

Debriefing: Meta-analyses Show No or Negative Effect



Debriefing

"Recent studies suggest that at times debriefing might be associated with a worse outcome"

McFarlane, (2006) "Can debriefing work? Critical appraisal of theories of interventions and outcomes with directions for future research."

If a reduction in fear memories associated with trauma is beneficial, then:

- a) Amnesia
- b) A repressive coping style
- c) Avoiding psychological interventions which **enhance** memories of the trauma
- d) Medications which interfere with memory?

PTSD and Cortisol



Activation of HPA axis

PTSD

Hypoplasticity of HPA axis

Pre-clinical study support the concept of "golden hours" and window of opportunity

Back to the clinic

"Window of Opportunities"



What do we do with patients who come to the ER after experiencing a trauma?

- Talk with them about the trauma
- Encourage them not to suppress, not to repress

• **BN7**



Benzodiazepines



Benzodiazepines and PTSD

What is the effect of BNZ on HPA axis?

Figure 12



Blocking the normal response of the HPA.

PTSD

Hypoplasticity of HPA axis

If decrease level of cortisol is associated with PTSD what would be the affect of giving BNZ?

Benzodiazepines and ASR Prospective study

N=26

<u>**Treatment</u></u> – 6.7 days after trauma (range 2-18 days)**</u>

- BNZ Clonazepam 2.7 mg/day or Alprazolam 2.5 mg/day
- **Design** Prospective F/U 1 and 6 months after trauma 13 patients with BNZ and 13 pair matched
- Scales –Horowitz Impact of Event ScaleMississippi rating scaleCAPS (Clinically administered PTSD scale)

Gelpin et al, J Clin Psychiatry, 1996

Results: BNZ and ASR prospective study

PTSD score & Anxiety score

no difference between BNZ and control at 1 and 6 months

PTSD diagnosis: 9/13 BNZ vs. 3/13 Control

<u>Conclusion</u>: Early administration of BNZ is <u>not</u> associated with a beneficial effect on the course of the illness

Gelpin et al, J Clin Psychiatry, 1996
Benzodiazepines: Studies Show Increased Risk of PTSD With Prolonged Use



Gelpin E et al. J Clin Psychiatry. 1996;57:390-394 Mellman TA et al. J Clin Psychiatry. 2002;62:1183-1184 †6 months and 6 weeks, respectively. All of depression occurred in the BZD group. *Alprazolam (n=3) or clonazepam (n=10) vs cases. no treatment (n=10) **Temazepan (n=11) vs placebo (n=10)



Long-term effects of alprazolam in the double-exposure (PSS) model on behavior at day 31 on anxiety-like behaviors:

- A) Time spent in the open arms of the EPM.
- B) Number of entries to the open arms
- C) Total exploration.
- D) Anxiety Index.

Double PSS-with the Alprazolam treatment regimen resulted in significantly decreased time spent in the open arms and total exploration on the maze, with a significantly increased Anxiety-Index, as compared to PSS-exposure with the saline by treatment regimen. All data represent group mean ± S.E.M



VA/DoD Clinical Practice Guideline

Management of Post-Traumatic Stress



VA/DoD Evidence Based Practice

VA/DoD Evidence Based Practice

Benzodiazepines and Stress related Disorders



Stress Related Disorders

Reactive Attachment Disorder Disinhibited Social Engagement Disorder Post Traumatic Stress Disorder Acute Stress Disorder Adjustment Disorders Other Specified Trauma- and Stressor-Related Disorder Unspecified Trauma- and Stressor-Related Disorder

Bereavement and Benzodiazepines

The British National Formulary (British Medical Association & Royal Pharmaceutical Society of Great Britain 2000), and the Committee on Safety of Medicines (Committee on Safety of Medicines 1998) advise **against** using **benzodiazepines** after bereavement and suggest that these agents may inhibit the grieving process.

British Medical Association & Royal Pharmaceutical Society of Great Britain (2000) British National Formulary (September). London & Wallingford: BMJ Books & Pharmaceutical Press.

Committee on Safety of Medicines (1988) Current Problems, No. 21.

PTSD and "golden hours"

Does psychiatry have a window of opportunity for treatment, as there is in other medical fields (such as in stroke or MI)?



Does psychiatry have a window of opportunity for treatment, as there is in other medical fields (such as in stroke or MI)?

Can we reach people within a short time of the trauma?

Could a single high dose of iv hydrocortisone prevent the development of PTSD?



Is there a window of opportunity for secondary prevention of PTSD?

Window of Opportunities?





Consolidation

* The transition from **UNStable** memory

to **stable** memory.

"Window of Opportunities"



Acute Treatment after Trauma

a. Examining the conventional approach.

b. Harnessing neuroscience to change the trajectory.

What do we do with patients who come to ER after experiencing a trauma?

What do we do with patients who come to ER after experiencing a trauma?

- * Talk with them about the trauma
- Encourage them not to suppress, not to repress
- * BNZ

 If we are not supposed to give BNZ and not to do debriefing what should we do?

What should we do with patients who come to the ER after a

trauma?

Carried out not by mental health profession (MEP) and therefore should be simple.

It includes :

Goals -- 3R (Ra, Rb, Rc)

1.) Return to full activity/functioning.

Carried out not by mental health profession (MEP) and therefore should be simple. It includes : Goals -- 3R (Ra, Rb, Rc) 1) Return to full activity/functioning.

2) Regain behavioral / emotional control

Carried out **not** by mental health profession (MEP) and therefore should be simple.

It includes :

Goals -- 3R (Ra, Rb, Rc) 1) Return to full activity/functioning.

2) Regain behavioral / emotional control

3) Restore interpersonal communication

Carried out not by MEP and therefore should be simple. It includes

Goals -- 3R (Ra, Rb, Rc) How to do it - ABN via RAISE. What not to do-- 3P. Management

ABN Addressing Basic Needs.

via ERASE

ABN- Addressing Basic Needs. via ERASE

- * Reduce Exposure to stress (i.e. finding secure place etc.)
- * Restore physiological needs (food, drink, hygiene etc.)
- * Provide InformAtion/ orientAtion.
- * Locate source of Support. (family, friends etc.)
- * Emphasizing the Expectation of returning back to normal.

Carried out not by MEP and therefore should be simple. It includes

- * Goals -- 3R (Ra, Rb, Rc)
- * How to do it ABN via RAISE.
- * What not to do-- 3P.

What MOT

to do-- 3P.

What not to do-- <u>3</u>P.

* Don't

Pathologize.

"Normal response to Abnormal situation."



What not to do-- <u>3</u>P.

* Don't Pathologize. * Don't Psychologize.

What not to do-- 3P.

- * Don't Pathologize.
- * Don't Psychologize: i.e. don't facilitate emotional reaction via group therapy, debriefing etc.

What not to do-- <u>3</u>P.

* Don't Pathologize.

* Don't Psychologize: ie don't facilitate emotional reaction via group therapy, debriefing etc.

* Don't P

What not to do-- 3P.

* Don't Pathologize.

- * Don't Psychologize: ie don't facilitate emotional reaction via group therapy, debriefing etc.
- * Don't Pharmacologize.

"Window of Opportunities"

- * BNZ not a good idea
- * Debriefing- """"""
- * Propanolol pilot data ~
- * Morphine retrospective data +
- * Cortisol animal data + pilot data +
- *** SSRI** animal data + human data +
- * Oxcytocin animal data +

SSRIs and sigma₁

Relative affinity¹ Fluvoxamine ≥ Sertraline > Fluoxetine > Citalopram >> Paroxetine

¹Narita et al (1996); ²Zanardi et al (1996); ³Gatti et al (1996)

The clinical consequences of sigma₁ activity Where does σ_1 fit in?


Conclusion

DSM IV Classification of Anxiety Disorders



A different approach is to look beyond the symptoms

Endophenotypical Approach



Section II: Diagnostic Criteria and Codes

- * Neurodevelopmental Disorders
- * Schizophrenia Spectrum and Other Psychotic Disorders
- * Bipolar and Related Disorders
- * Depressive Disorders
- * Anxiety Disorders
- * Obsessive-Compulsive and Related Disorders
- * Trauma- and Stressor-Related Disorders
- * Dissociative Disorders
- * Somatic Symptom and Related Disorders
- * Feeding and Eating Disorders
- * Elimination Disorders
- * Sleep-Wake Disorders
- * Sexual Dysfunctions
- * Gender Dysphoria
- * Disruptive, Impulse-Control, and Conduct Disorders
- * Substance-Related and Addictive Disorders

When – 1. Time of intervention

Treatment of Chronic PTSD



"Window of Opportunities"



Does psychiatry have a window of opportunity for treatment, as there is in other medical fields (such as in stroke or MI)?



Is there a window of opportunity for secondary prevention of PTSD?

Window of Opportunities?





Consolidation

* The transition from **UNStable** memory

to **stable** memory.

PTSD and Cortisol

"Window of Opportunities"

- * BNZ not a good idea
- * Debriefing- """"""
- * Propanolol pilot data ~
- * Morphine retrospective data +
- * Cortisol animal data + pilot data +
- ***** SSRI animal data + human data +
- * Oxcytocin animal data +

Early post-exposure





An Integrative Approach to Secondary Prevention of PTSD

- 1. Expectation that individuals return to full activity
- 2. Ensuring support
- 3. 3P

What not to do-- 3P.

* Don't Pathologize.

- * Don't Psychologize: ie don't facilitate emotional reaction via group therapy, debriefing etc.
- * Don't Pharmacologize.

To be further explored – An Integrative Approach to Secondary Prevention of PTSD

- 1. Early and short (3 to 4 months) SSRI's administration ?
- 2. Cortisol administration ?
- 3. Sleep deprivation ?
- 4. Oxytocin administration ?
- 5. Specific cognitive task?

Thanks